BEIJING (Reuters) - Levels of an antibody found in recovered COVID-19 patients fell sharply in 2-3 months after infection for both symptomatic and asymptomatic patients, according to a Chinese study, raising questions about the length of any immunity against the novel coronavirus. The research, published in Nature Medicine on June 18, highlights the risks of…

Trump's Arizona Rally Site Church Claims New Tech Kills COVID ... Most of It, Anyway 6/22/2020 7:02 AM PT The church where President Trump will host his latest rally since the pandemic has made some bold claims about its facility and coronavirus, and it sounds too good to be true. Dream City Church Faith leaders…

Months into the new coronavirus pandemic, researchers are grappling with an urgent question: How much risk do we have of catching COVID-19 — or dying from it — from our chance encounters? The debate has flared as authorities find themselves alternately accused of moving too fast or not fast enough in easing restrictions so more…

HuffPost is part of Verizon Media. Click 'I agree' to allow Verizon Media and our partners to use cookies and similar technologies to access your device and use your data (including location) to understand your interests, and provide and measure personalised ads. We will also provide you with personalised ads on partner products. Learn more…

Pfizer (NYSE:PFE) has initiated Phase 3 clinical trials on vaccine candidates for preventing pneumonia, RSV and meningitis. 20-valent pneumococcal vaccine (20vPnC): Two studies, NCT04382326 and NCT04379713, will assess a four-dose series in healthy infants. The former is aimed at determining immunologic non-inferiority to Prevnar 13.  RSV vaccine (RSVpreF): Study NCT04424316 is assessing the vaccine in infants…